Skip to main content

Table 2 Flow cytometry of platelets with activation

From: Novel SLFN14 mutation associated with macrothrombocytopenia in a patient with severe haemorrhagic syndrome

Platelet parameters

Control range

Patient

Units

Platelet count

229 (219–376)*

40

×109/L

FSC (platelet size)

 

At rest

107 (81–121)

131

%

Activated

69 (54–79)

100

%

FSC ratio at rest / after activation

1.53 (1.37–2.09)

1.31

Ratio

SSC (platelet granularity)

 

At rest

84.6 (70-93.4)

118

%

Activated

84.2 (57.5–66.9)

121

%

SSC ratio at rest / after activation

1.19 (1.11–1.58)

0.98

Ratio

GP Ib (CD42b antigen)

 

At rest

99 (68–118)

107

%

Activated

57 (46–71)

79

%

CD42b ratio at rest/after activation

1.71 (1.43–2.39)

1.35

Ratio

GP IIIa (CD61 antigen)

 

At rest

98 (91–113)

104

%

Activated

261 (211–352)

352

%

CD61 ratio after activation / at rest

2.58 (2.28–3.45)

3.38

Ratio

PAC-1 binding (activated GP IIb/IIIa)

 

At rest

3.31 (3.02–4.1)

6.1

%

Activated

116 (76–165)

45

%

PAC-1 ratio after activation / at rest

36 (21–48)

7.38

Ratio

Fluorescence of loaded mepacrine in dense granules

 

At rest

85 (73–118)

156

%

Activated

22 (19–35)

57

%

Dense granules release Index at rest/after activation

4.1 (2.2–4.8)

2.7

Ratio

P-selectin (CD62p antigen)

 

At rest

2.35 (2.1-4)

2.8

%

Activated

93 (78–114)

99

%

Release index of α-granules (by CD62p) after activation / at rest

41 (20-47.5)

35.4

Ratio

Fraction of procoagulant PS + platelets (by Annexin V)

 

At rest

0.3 (0.05–0.7)

0.32

%

Activated

19 (6.2–37.1)

14.0

%

  1. *median (min-max); values in bold are out of the normal range.